Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with Dr Michael Gordon (HonorHealth Research Institute).
‘Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What is sabizabulin and what is the rationale for its use in the treatment of COVID-19? (00:21)
- What were the aims, design and eligibility criteria of the VERU-111 clinical trial? (02:05)
- What were the primary and secondary endpoints, and how well were they achieved? (04:38)
- What was the safety profile of sabizabulin? (06:57)
- What were the limitations of the study and what further studies are needed? (08:06)
Disclosures: Michael Gordon is a consultant for OnQuality, Viracta, Qualigen, Leaderboard and MorphicTx; he receives grant/research support from Veru, FujiFilm, ATEA, Beigene, Incyte, Kinevant, Redhill and Syndax; he is on the Advisory Board for Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022
Share this Video
Related Videos In COVID-19
Findings from the COVA study of BIO101 in severe COVID-19: Girish B. Nair, ATS 2023
The COVA study (NCT04472728) was a double-blind, placebo-controlled phase 2 to 3 study that investigated BIO101 for the prevention of respiratory deterioration in hospitalized COVID-19. touchRESPIRATORY were delighted to speak with Dr. Girish B. Nair (Beaumont Health, Royal Oak, MI, USA) around the mechanism of action of BIO101, the design, inclusion criteria and findings from […]
Margaret Pisani, Research highlights in COVID-19 from 2022
Longitudinal studies into the long-term impact of COVID-19 are currently at the forefront of research, touchRESPIRATORY interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) about what to look out for in 2023 in this area. Disclosures: Margaret Pisani has nothing to disclose in relation to this video interview. Support: Interview and filming […]
Alan Kaplan: IPCRG COVID-19 and Respiratory Q&A – COVID-19 Controversies, Vaccination and Booster Doses
The IPCRG COVID-19 and Respiratory Q&A is providing evidence based COVID and respiratory advice to practising primary care clinicians. Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) answers questions from the Q&A on managing COVID-19, how to address the controversies surrounding the COVID-19 vaccines, and the immunity provided from COVID-19 vaccination and booster doses. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!